Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

Inclusion Criteria:

1. men and women 18 years or older

2. Elevated LDL-C on current lipid lowering therapy and; prior atherosclerotic
cardiovascular disease (CVD) event or evidence of CVD or without CVD but at high risk
for CVD based on American Heart Association/American College of Cardiology (AHA/ACC)
CVD risk calculator, or aged 40 years and older with diabetes and moderate- to
high-intensity statin, or pre-treatment LDL-C 190 mg/dL or greater or heterozygous
familial hypercholesterolemia (HeFH)

3. patients who met original entry criteria in, and completed, the double-blind,
placebo-controlled 16-week Phase 2 study (LIB003-002)

Exclusion Criteria:

1. patients who did not who complete the double-blind, placebo-controlled 16-week Phase 2
study (LIB003-002)

2. <18 years of age

3. pregnant or women of childbearing potential not using acceptable birth control